Oppenheimer lowered the firm’s price target on Perspective Therapeutics (CATX) to $16 from $22 and keeps an Outperform rating on the shares. The firm views yesterday’s selloff as an overreaction to early data from the dose escalation phase of the VMT-alpha-NET program. The data demonstrated clinical activity that aligns with dose intensity and a clean safety profile supporting further dose escalation, the analyst tells investors in a research note. Opco would be a buyer on weakness here with Perspective trading near cash levels.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Perspective Therapeutics selloff a buying opportunity, says JonesResearch
- Perspective Therapeutics Inc trading resumes
- Perspective Therapeutics Inc trading halted, volatility trading pause
- Perspective Therapeutics to pursue dose escalation in Phase 1/2a clinical trial
- Perspective Therapeutics Reports Strong Cash Position and Clinical Advances